111 results about "Toxoid" patented technology

The invention provides active and passive immunization methods for preventing and treating Clostridium difficile infection, which involve percutaneous administration of C. difficile toxin-neutralizing polyclonal immune globulin, C. difficile toxoids, or combinations thereof. Also provided by the invention are C. difficile toxoids, C. difficile toxin-neutralizing polyclonal immune globulin, and methods of identifying subjects that produce C. difficile toxin-neutralizing polyclonal immune globulin.

A pharmaceutical composition has a therapeutically effective amount of at least one of: a pharmaceutically active nasal peptide, its pharmaceutically acceptable salt and its peptidic fragment. The composition also contains an absorbefacient effective amount of THAM in a pharmaceutically acceptable, aqueous liquid diluent or carrier. The composition is provided in a convenient form for nasal administration. In one embodiment, the peptidic fragment may be selected physiologically active lymphokines and monokines, peptidic enzymes, proteic vaccines, peptidic toxoids and personalized proteins derived from genoma. In another embodiment, the peptidic fragment may be selected from the peptide hormones and hormone antagonists buserelin, desmopressin, vasopressin, angiotensin, felypressin, octreotide, somatropin, thyrotropin (TSH), somatostatin, gosereline, thryptorelin and insulin selected from the group consisting of cow and pig, synthetic and recombinant.

An immunogenic detoxified protein is provided which comprises the amino acid sequence of subunit A of an E. coli heat labile toxin (LT-A) or a fragment thereof in which at least amino acid Ala-72 of the A subunit is mutated, preferably by substitution with Arg. The toxoid is useful as vaccine against an enterotoxigenic strain of E. coli and is produced by recombinant DNA means by site-directed mutagenesis. It is also an effective adjuvant.

The present invention relates to toxoid preparations comprising a non-disrupted and/or a non-denatured toxin associated with a particulate vector that minimizes or precludes said toxin from inflicting damage at an action site of said toxin. The present invention also relates to immunogenic compositions or vaccines comprising the toxoid preparations, and the methods of using the toxoid preparations, immunogenic compositions or vaccines.

The invention discloses an antibody for broad-spectrum detection of Bt Cry1 toxoids as well as a preparation method and application thereof. The antibody is generated by secretion of hybridoma cells with the collection number of CCTCC NO:C2015145, obtained after coupling antigen polypeptide SEQ ID NO.2 and carrier protein KLH and then immunizing Balb/c mice. The ratio of the antibody to OD450 of six kinds of Bt Cry1 toxoids to negative holes (PBS solution) is far larger than 2.1, and the antibody has relatively high titer, has a broad-spectrum detection effect on the Bt Cry1 toxoids and makes up the blank of the broad-spectrum detection field of the Bt Cry1 toxoids.

Acellular pertussis vaccines comprise purified toxin or toxoid thereof, filamentous haemagglutinin, pertactin and fimbrial agglutinogens formulated to confer protection to at least 70% of members of an at-risk population. The fimbrial agglutinogens may be prepared from a Bordetella strain, particularly a B. pertussis strain, by a multiple step procedure involving extraction of the fimbrial agglutinogens from cell paste and concentrating and purifying the extracted material.

The invention discloses feed active egg powder with nutrition, healthcare and growth promotion functions and a production method thereof, wherein the feed active egg powder with nutrition, healthcare and growth promotion functions is obtained by fully mixing weighed enterotoxin-resistant Escherichia coli tetravalent yolk antibody, C-type clostridium perfringens and beta toxoid-resistant divalent yolk antibody, rotavirus-resistant yolk antibody, transmissible gastroenteritis and epidemic diarrhea-resistant bigeminal yolk antibody, cholecystokinin/somatostatin-resistant double-fusion white and yolk antibody, lysozyme meringue powder, epidermal growth factor-containing meringue powder, common meringue powder and silica (antitackiness agent) for 60 to 100 seconds. The feed active egg powder with nutrition, healthcare and growth promotion functions provided by the invention has the beneficial effects of containing high-quality protein, fat and amino acid required for the growth and development of piglets, containing lysozyme, yolk antibody and epidermal growth factor for preventing disease, protecting health and promoting growth, and having four efficacies of enhancing the feed intake,accelerating the growth, boosting the immunity and controlling the diarrhea of the piglets before and after weaning.